Generation of activated killer cells in tumor-bearing hosts
- 15 February 1987
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 39 (2) , 232-239
- https://doi.org/10.1002/ijc.2910390218
Abstract
Activated killer (AK) cells were generated in spleen-cell cultures derived from tumor-bearing hosts (TS) whereas, under the same conditions, cultured normal spleen cells (NS) gave little cytotoxicity. The AK effectors were primarily Thyl+, AGMI- and Lyt2- and thus were neither classic cytotoxic T lymphocyts (CTL) nor classic NK cells. These AK cells selectively killed tumor targets of different etiologic origins and did not kill concanavalin-A-induced lymphoblasts. The broad target-cell reactivity of these AK cells was also confirmed by cold target-inhibition experiments. Generation of AK cell correlated with interleukin-2 (IL-2) production, and the levels of AK cells generation paralleled those of IL-2 production. Furthermore, the generation of AK cells was blocked by the anti-IL-2 receptor monoclonal antibody (MAb) (αIL-2R), indicating that IL-2 was involved, and thus these AK cells were lymphokine-activated killer (LAK) cells. We previously showed that the expression of AGMI on LAK precursors disappeared when they differentiated into LAK effectors, indicating that the activated LAK cells lacked AGMI. When examining the serologic phenotype of the LAK precursors in tumor-bearing hosts, we found that they lacked AGMI, which suggested that these LAK precursors were in an “activated” state. These cells were still Thyl-, and were thus different from fully activated LAK effectors which were Thyl+ cells, indicating that the full differentiation of LAK cells in vivo was arrested in the tumor-bearing hosts. We also found that the presence of small amounts of X-irradiated tumor cells prevented the generation of AK cells. These findings suggest that, in the tumor-bearing hosts, the presence of tumor cells triggers the activation of AK precursors; however, the same tumor cells may also be immunosuppressive, which prevents the full differentiation of AK precursors into AK effectors.This publication has 22 references indexed in Scilit:
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- The generation of culture activated killer cells (AK) is interleukin‐2‐dependent and requires self‐ia recognitionInternational Journal of Cancer, 1985
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of Experimental Medicine, 1984
- Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex.Proceedings of the National Academy of Sciences, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Monoclonal Antibodies Against Rat Immunoglobulin Kappa ChainsHybridoma, 1982
- Switching on the macrophage-mediated suppressor mechanism by tumor cells to evade host immune surveillance.Proceedings of the National Academy of Sciences, 1980
- Natural Cell-Mediated ImmunityPublished by Elsevier ,1978
- Progressive Loss of H-2 Antigens With Concomitant Increase of Cell-Surface Antigen(s) Determined by Moloney Leukemia Virus in Cultured Murine Lymphomas23JNCI Journal of the National Cancer Institute, 1973
- Studies in Antibody Response of Mice to Tumour InoculationBritish Journal of Cancer, 1950